Sigyn Therapeutics (SIGY)
OTHER OTC:SIGY
Top Page
No summary available
Positive Factors
Innovative Technology
The company's proprietary blood purification technology addresses critical medical needs, offering potential for strong market demand and strategic partnerships in healthcare.
Negative Factors
Financial Instability
Persistent financial difficulties indicate challenges in achieving profitability and sustainability, posing risks to long-term operational viability and investor confidence.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Technology
The company's proprietary blood purification technology addresses critical medical needs, offering potential for strong market demand and strategic partnerships in healthcare.
Read all positive factors
Sigyn Therapeutics (SIGY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.69K
Dividend YieldN/A
Average Volume (3M)1.22K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue GrowthN/A
EPS Growth37.25%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.20
Shares Outstanding1,605,377
10 Day Avg. Volume2,995
30 Day Avg. Volume1,222
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market Cap53.78
Enterprise Value/Revenue481.52
Enterprise Value/Gross Profit963.03
Enterprise Value/Ebitda-1.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.8
Revenue Forecast (FY)N/A
Sigyn Therapeutics Business Overview & Revenue Model
Company Description
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory diso...
How the Company Makes Money
Sigyn Therapeutics generates revenue primarily through the commercialization of its blood purification technology, which targets hospitals and healthcare providers treating patients with severe inflammatory conditions. The company may also engage ...
Sigyn Therapeutics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.89K | 0.00 | -8.86K | -10.45K | ― | -11.30K |
| EBITDA | -2.00M | -2.52M | -2.45M | -2.14M | -2.53M | -905.13K |
| Net Income | -3.22M | -3.34M | -4.15M | -3.71M | -3.40M | -1.60M |
Balance Sheet | ||||||
| Total Assets | 135.57K | 213.72K | 321.81K | 332.88K | 710.26K | 694.08K |
| Cash, Cash Equivalents and Short-Term Investments | 85.57K | 12.14K | 11.69K | 8.36K | 340.96K | 84.40K |
| Total Debt | 2.81M | 2.19M | 2.40M | 1.88M | 980.01K | 518.67K |
| Total Liabilities | 6.05M | 4.67M | 3.73M | 2.24M | 974.84K | 594.90K |
| Stockholders Equity | -5.92M | -4.46M | -3.41M | -1.90M | -264.58K | 99.18K |
Cash Flow | ||||||
| Free Cash Flow | -936.43K | -872.44K | -1.38M | -1.83M | -1.80M | -840.61K |
| Operating Cash Flow | -936.43K | -872.44K | -1.38M | -1.83M | -1.77M | -829.81K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -860.00 | -29.26K | -10.80K |
| Financing Cash Flow | 857.21K | 872.89K | 1.39M | 1.50M | 2.06M | 925.01K |
Sigyn Therapeutics Technical Analysis
Negative
0.03
Price Trends
0.26
Negative
0.90
Negative
1.88
Negative
Market Momentum
-0.06
Negative
31.00
Neutral
67.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGY, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.26, and below the 200-day MA of 1.88, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 31.00 is Neutral, neither overbought nor oversold. The STOCH value of 67.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SIGY.
Sigyn Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $51.69K | -2.60 | ― | ― | ― | 37.25% | |
47 Neutral | $10.59M | -0.10 | -209.36% | ― | ― | 83.25% | |
44 Neutral | $4.87M | -0.28 | -203.36% | ― | ― | 90.53% | |
43 Neutral | $3.68M | -0.12 | -215.04% | ― | -100.00% | 93.82% | |
42 Neutral | $4.73M | -0.13 | -317.98% | ― | ― | 34.57% | |
42 Neutral | $4.35M | -0.22 | -0.40% | ― | ― | 96.26% |
* Healthcare Sector Average
SIGY
Sigyn Therapeutics
0.03
-3.92
-99.19%
TOVX
Theriva Biologics
0.23
-0.91
-79.82%
INDP
Indaptus Therapeutics
2.11
-11.33
-84.30%
REVB
Revelation Biosciences
1.17
-36.99
-96.93%
DRMA
Dermata Therapeutics
1.22
-6.86
-84.90%
AZTR
Azitra Inc
0.23
-1.71
-88.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―